PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12497720

[Update on Acinetobacter baumannii].

Marie-Laure Joly-Guillou
View original source ↗Export metadata ↓

Abstract

RESISTANCE TO IMIPENEM: The increase in the prevalence of A. baumannii resistance is worrying because of the diversity of the enzymes implicated in the resistance and its epidemic diffusion that is always difficult to handle. BROAD SPECTRUM BETA-LACTAMASE: Still rare in Acinetobacter, a broad spectrum beta-lactamase has been demonstrated in a strain isolated during a urinary infection and at the origin of an outbreak. RISK FACTORS: Other than the classic risk factors, a survey regrouping the data from 28 Spanish hospitals showed that hospitalisation in an intensive care unit and the administration of an inappropriate antibiotherapy are two risk factors of mortality during Acinetobacter infections. DEPENDING ON THE PRODUCTION OF SLIME: An antibiotherapy must be administered earlier in strains producing slime than in strains that do not. TO FIGHT ACINETOBACTER: It is essential to break the epidemic chain. In addition to this priority measure, a policy of correct antibiotic use must be installed.

Explore related subjects

Acinetobacter InfectionsAcinetobacter baumanniiAnti-Bacterial AgentsDisease OutbreaksDrug ResistanceHospitalsHumansIncidenceIntensive Care UnitsRisk FactorsSpainJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Marie-Laure Joly-Guillou. 2002-11-30. [Update on Acinetobacter baumannii].. https://pubmed.ncbi.nlm.nih.gov/12497720/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia.

OBJECTIVES: To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. METHODS: A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. RESULTS: Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P < 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P < 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P < 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). CONCLUSIONS: Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.

Acinetobacter Infections↗
PubMed2007

Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin.

The effect of colistin on bacterial eradication and survival was tested in experimental infection by multidrug-resistant Acinetobacter baumannii. The thigh infection model was applied in 86 neutropenic Wistar rats. Six rats were used for the induction of neutropenia and for the selection of the dose regimen of colistin; the remainder was equally divided into four groups: A, controls; B, rifampicin; C, colistin; and D, both agents. Therapy was administered 5 h after bacterial challenge; 5mg/kg of rifampicin was administered intravenously and 3mg/kg of colistin intramuscularly. Survival was recorded in 10 animals of each group. The remaining 10 rats per group were killed 4h after therapy; blood and tissue samples were sampled. Median survival of animals of groups A, B, C and D was 2.00, 2.50, 4.00 and 4.00 days, respectively (P=0.0048 between A and C and P=0.0012 between A and D. Mortality rates after 6 days of follow-up were 100, 100, 100 and 70%, respectively (P=0.018 between groups). Statistically significant decreases of bacteria were found in blood, liver, lung and spleen of group B compared with A; in lung of group C compared with A; and in blood and liver of group D compared with A. Colistin was effective in prolonging survival in an experimental thigh infection by multidrug-resistant A. baumannii in neutropenic rats. Its activity was enhanced after co-administration with rifampicin. These results mandate the application of colistin in the event of infections by multidrug-resistant pathogens and the need for its co-administration with rifampicin.

Acinetobacter Infections↗